stockrowRepligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
Follow RGEN
Alert me
Repligen Corporation (RGEN) EPS (diluted)
Repligen Corporation's EPS (diluted) for fiscal 2025 was $0.86, compared with −$0.46 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.21. Over the past ten years it has ranged from −$0.46 (fiscal 2024) to $3.24 (fiscal 2022); the current reading is higher than 73% of that period. Repligen Corporation ranks 29th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.86 | — |
| FY2024 | −$0.46 | — |
| FY2023 | $0.63 | (80.56%) |
| FY2022 | $3.24 | 44.64% |
| FY2021 | $2.24 | 101.80% |
| FY2020 | $1.11 | 152.27% |
| FY2019 | $0.44 | 18.92% |
| FY2018 | $0.37 | (48.61%) |
| FY2017 | $0.72 | 111.76% |
| FY2016 | $0.34 | 21.43% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.68 | — |
| Jun 2026 | $0.09 | (40.00%) |
| Mar 2026 | $0.15 | (34.78%) |
| Dec 2025 | $0.23 | (11.54%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALGN Align Technology, Inc. compare | $6.87 |
| ATR AptarGroup, Inc. compare | $4.12 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| SOLV Solventum Corporation compare | $0.89 |
| AVTR Avantor, Inc. compare | $0.50 |
| RGEN Repligen Corporation | −$0.21 |
| BLCO Bausch + Lomb Corporation compare | −$0.30 |
| BAX Baxter International Inc. compare | −$1.41 |
| TFX Teleflex Incorporated compare | −$23.29 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RGEN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement